Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Payables (2016 - 2026)

Gyre Therapeutics has reported Payables over the past 16 years, most recently at $124000.0 for Q4 2025.

  • Quarterly Payables rose 14.81% to $124000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124000.0 through Dec 2025, up 14.81% year-over-year, with the annual reading at $124000.0 for FY2025, 14.81% up from the prior year.
  • Payables was $124000.0 for Q4 2025 at Gyre Therapeutics, down from $556000.0 in the prior quarter.
  • Over five years, Payables peaked at $7.7 million in Q4 2022 and troughed at $5000.0 in Q2 2023.
  • The 5-year median for Payables is $316500.0 (2024), against an average of $1.5 million.
  • Year-over-year, Payables plummeted 99.66% in 2023 and then surged 5320.0% in 2024.
  • A 5-year view of Payables shows it stood at $6.4 million in 2021, then grew by 19.64% to $7.7 million in 2022, then tumbled by 95.38% to $355000.0 in 2023, then tumbled by 69.58% to $108000.0 in 2024, then grew by 14.81% to $124000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Payables are $124000.0 (Q4 2025), $556000.0 (Q3 2025), and $71000.0 (Q2 2025).